Kinases (Tyrosine Specific Protein)
Tyrosine specific kinases form a large family of enzymes that are responsible for catalyzing the transfer of ATP to specific tyrosine residues in target proteins. In turn, the phosphorylation of tyrosine residues causes a change in the function of the protein that they are contained in. They function in a variety of processes, signal transduction pathways, and actions, and may be responsible for key events in the body[1]. Axon Ligands™ that interact with tyrosine specific enzymes that are part of the JAK/STAT signaling pathway have been categorized independently. The remainder of Axon Ligands™ that lack interactions with tyrosine kinases of this particular signaling pathway are listed here, grouped on the basis of their selectivity.
[1] Receptor tyrosine kinase signaling: a view from quantitative proteomics. J. Dengjel,I. Kratchmarova, B. Blagoev. Mol. Biosyst. 2009, 5, 1112-1121.
| Axon ID | Name | Description | From price | |
|---|---|---|---|---|
| 3973 | XL-228 | Multitargeted protein kinase inhibitor (IGF1R, Aurora,FGFR, ABL,ALK and SRC) | Inquire | |
| 2381 | WH-4-023 | Orally active src-family selective lck inhibitor | €90.00 | |
| 3099 | TL02-59 | Potent, selective and orally active Fgr and Lyn inhibitor | €120.00 | |
| 2560 | Tilfrinib | Brk inhibitor with antiproliferative activity in breast tumor cells | €95.00 | |
| 2130 | Stem Cell Alternative 2i inhibitor Set | Set of SRC inhibitor CGP77675 (Axon 2097) and GSK-3 inhibitor CHIR99021 (Axon 1386) | €110.00 | |
| 1407 | SKI 606 | Bcr-Abl and Src tyrosine kinase inhibitor | €75.00 | |
| 2459 | PND 1186 | Orally active dual FAK/PYK2 inhibitor triggering cell apoptosis in tumor cells | €90.00 | |
| 1623 | PF 573228 | FAK inhibitor | €95.00 | |
| 5011 | Naive Stem Cell 5i inhibitor Set | Set of five inhibitors for the induction and maintenance of human naive stem cell pluripotency | €200.00 | |
| 2121 | INNO 406 | Dual Bcr-Abl and Lyn kinase inhibitor | €85.00 | |
| 3717 | GSK2256098 | FAK inhibitor | Inquire | |
| 2574 | Defactinib | Orally available second generation inhibitor of FAK and PYK2 | €80.00 | |
| 1392 | Dasatinib | Bcr-Abl and Src tyrosine kinase inhibitor | €90.00 | |
| 2992 | CTx-0294885 | Broad-spectrum kinase inhibitor | €90.00 | |
| 2005 | ASP 3026 | Inhibitor of the oncogenic fusion kinase EML4-ALK | €80.00 | |
| 1698 | A 770041 | Orally active src-family selective lck inhibitor | €140.00 | |